PDXs, ending in an “x”, are patient direct and have never been in vitro. Xenografts ending in “m” are established from a cell line.
The defination for the abbreviation are given below the table. Please scroll all the way down.
Please click at the top logo to return to home page.
1 - Phase of therapy for the patient at the time the specimen used to derive the cell line was obtained
Dx (Diagnosis): cell lines derived from samples of patients prior to treatment
PD (Progressive Disease): cell lines derived from samples of patients who relapsed after chemotherapy
PD-BMT: cell lines derived from samples of patients who relapsed after chemotherapy and bone marrow transplantation
PD-PM: cell lines derived from samples of post-mortem patients who relapsed after chemotherapy
BM- Bone Marrow
2 -MYCN oncogene amplification
N: MYCN Non-Amplified
A: MYCN Amplified
3 - TP53 gene function
4 - EWS/FLI1 Status
FLI1: friend leukemia insertion - chromosome 11, t(11;22)
ERG: ets-related gene - chromosome 21, t(21;22)
WT: Wild Type
TMM:Telomere Maintenance mechanism
✓ = Available/available upon request
SQ- subcutaneous injection
TV- intravenous (tail vein)
EST- ever shorter telomeres, i.e. telomerase and ALT negative
TERT+- telomerase positive
ALT - alternate lengthening of telomeres, C-circle positive
Cyclo + Topo - PDX was assessed for response in mice to cyclophosphamide + topotecan.
WES - Whole Exome Secovencing